Evidence map›Paper›PMID 36709149›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2022

[Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].

F M Song, Y X Hu, M M Zhang, W W Wu, H J Xu, H S Zhang, H Huang, G Q Wei

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

F M SongBone Marrow Transplantation Center, Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 311100, China.
Y X HuBone Marrow Transplantation Center, Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 311100, China.
M M ZhangBone Marrow Transplantation Center, Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 311100, China.
W W WuBone Marrow Transplantation Center, Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 311100, China.
H J XuBone Marrow Transplantation Center, Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 311100, China.
H S ZhangClinical Transformation Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200438, China.
H HuangBone Marrow Transplantation Center, Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 311100, China.
G Q WeiBone Marrow Transplantation Center, Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 311100, China.
First Affiliated Hospital Zhejiang University · CNShanghai Pulmonary Hospital · CN

Funding

General Project of the National Natural Science Foundation of China 81870153Key projects of the National Natural Science Foundation of China 81730008, 82130003key R & D Program of Zhejiang Province 2019C03016, 2018C03016-2
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hematopoietic Stem Cell TransplantationPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenAntigens, CD19HumansImmunotherapy, AdoptiveNeurotoxicity SyndromesT-LymphocytesAntigens, CD19cell-associated neurotoxicityReceptors, Chimeric AntigenAcute lymphoblastic leukemia acuteChimeric antigen receptor T cellHumanizedRefractoryRelapsed

Identifiers

PMID36709149
PMCPMC9593019
OpenAlexW4318451950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.